PDS Biotechnology Corporation - Common Stock (PDSB)

PDSB Q1 2026 Earnings Transcript

PDS Biotechnology (NASDAQ:PDSB) reported a smaller first-quarter loss and highlighted changes to its late-stage head and neck cancer trial that management said could shorten development timelines and reduce costs. On the company’s first quarter 2026 earnings call, Chief Executive Officer Dr. Frank

PDS Biotech (PDSB) Q3 2025 earnings beat EPS estimates, sparking a major pre-market surge. The clinical-stage biotech also announced key progress for its lead cancer therapy.

The company requested a meeting with the FDA to discuss an accelerated approval pathway for its lead cancer drug, PDS0101, following strong final data from its VERSATILE-002 trial.

Q3 revenue of $995.7 million beat Align’s own forecast range of $965 million to $985 million, fueled by strong growth in clear aligners for teens and kids.

PDS Biotechnology (PDSB) reported Q2 2025 EPS of -$0.21, beating estimates. Stock rose 8.13% pre-market as clinical progress, including ASCO presentations, boosts investor optimism. No revenue yet.

The company said the reduced losses were primarily due to decreased operating expenses.

PDSB stock results show that PDS Biotechnology beat analyst estimates for earnings per share the second quarter of 2024.